Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Key Takeaways Tirzepatide is a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight
Start Now References European Medicines Agency, 2025
People with knee osteoarthritis often face a difficult cycle, where pain hinders their ability to exercise, but regular physical activity could help manage their symptoms
Al-Qahtani AA, Ba-Ali S, Alabduljalil T, Coyner AS, Patel RC, Weleber RG, Girach A, Christensen SK, Larsen M, Pennesi ME, Yang P
In mice models, there was a reduction in hyperglycemia, weight loss and increased energy expenditure compared to liraglutide [68,69]
Coverage for tirzepatide varies among insurers, but many now include it for weight management with prior approval
US$ 23.32
US$ 20.87
US$ 25.39
US$ 25.98
